ReviewFrontiers of oral biology2012
Paradigm shift in the pharmacological management of periodontal diseases.
Review in Frontiers of oral biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Influence of Natural Killer Cells and Natural Killer T Cells on Periodontal Disease: A Systematic Review of the Current Literature.International journal of molecular sciences · 2020Pooled it
- Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.The Journal of clinical investigation · 2021Trial
- An oral health optimized diet can reduce gingival and periodontal inflammation in humans - a randomized controlled pilot study.BMC oral health · 2016Trial
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- The Oral-Gut-Brain Axis: From Periodontal Dysbiosis to Neuroinflammation-Mechanistic Pathways, Salivary and Intestinal Biomarkers, and Therapeutic Targets: A Narrative Review.Dentistry journal · 2026Review
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Resolvin E1 and calvarial defects in rats: a comprehensive histological analysis.The Saudi dental journal · 2025Article
- The prohibitin ligand IN44 decreases Porphyromonas gingivalis mediated inflammation.BMC oral health · 2024Article
- Relationship between Carotid Intima-Media Thickness, Periodontal Disease, and Systemic Inflammation Biomarkers in an Adult Population.Biomedicines · 2024Article
- Resolvins as a Treatment Modality in Experimental Periodontitis: A Systematic Review of Preclinical Studies.Cureus · 2022Review
- Characterization of an ester-based core-multishell (CMS) nanocarrier for the topical application at the oral mucosa.Clinical oral investigations · 2021Article
- Selective Antimicrobial Therapies for Periodontitis: Win the "Battle and the War".International journal of molecular sciences · 2021Review
- Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review.European journal of oral sciences · 2021Review
- Nutrition as a Key Modifiable Factor for Periodontitis and Main Chronic Diseases.Journal of clinical medicine · 2021Article
- NETs Are Double-Edged Swords with the Potential to Aggravate or Resolve Periodontal Inflammation.Cells · 2020Review
- Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy.Periodontology 2000 · 2020Review
- PTEN Inhibits Inflammatory Bone Loss in Ligature-Induced Periodontitis via IL1 and TNF-BioMed research international · 2019Article
- The oral microbiota: dynamic communities and host interactions.Nature reviews. Microbiology · 2018Review
- Revisiting the Page & Schroeder model: the good, the bad and the unknowns in the periodontal host response 40 years later.Periodontology 2000 · 2017Review
- Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.Seminars in immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
It is becoming clear that variations in inflammatory response are a major determinant in susceptibility to periodontitis. However, our understanding of the relationship of the causal agents in periodontitis to the pathogenesis is not as clear as we once thought, and thus therapies based on etiopathogenesis are similarly in question. We are entering a new era of therapeutic discovery that may have a major impact on our management of the periodontal diseases. Fundamentally, periodontitis is an irreversible condition and once both soft and hard tissues are lost, the healthy periodontal architecture cannot be completely or predictably rebuilt. The discovery of new families of lipid mediators of resolution of inflammation (the lipoxins) and eicosapentaenoic-acid- and docosahexaenoic-acid-derived chemical mediators (the resolvins and protectins) opens new avenues to designing resolution-targeted therapies to control the unwanted side effects of excessive inflammation. The novel protective and therapeutic actions of pro-resolution lipid mediators following microbial challenge are mediated by regulation of the local and systemic inflammatory response that has a direct impact on the organization of the biofilm (plaque) and suggests a new paradigm in clinical periodontal therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.